Skip to main content
Caplight Logo









Gylden Pharma Limited

Gylden Pharma Limited

Private
AbingdonHealthcare & Life Scienceshttps://www.gyldenpharma.com/

Last Round

Grant

Nov 17, 2023

Total Funding Raised

$14.53M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Gylden Pharma Limited is a clinical-stage biotechnology company that develops synthetic T cell-priming vaccines and immunotherapies for infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

microneedle array patchMAPT cell-priming vaccinenanoparticle deliveryimmunotherapydrug delivery systemimmunopeptidomicssynthetic vaccinevaccine platformligandomebiotech R&Ddrug discoveryneedle-free injectionpandemic preparednessclinical-stage biotechAI drug discoverytransdermal delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gylden Pharma Limited Comparables

Compare Gylden Pharma Limited with similar companies based on industry and business-model similarity.

Gylden Pharma Limited comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Verndari, Inc.
81%
Uvax Bio, LLC
79%
Micron Biomedical
77%

Gylden Pharma Limited Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 17, 2023
VC RoundJun 20, 2023
GrantFeb 22, 2022
VC RoundNov 18, 2020
Series AJan 9, 2020
Grant
Apr 5, 2017

Key People

Founding team and executive leadership

Thomas Rademacher

Founder and CEO

Founding Team

Laurens Rademacher

Chief Technology Officer

Executive Team

Gylden Pharma Limited Investors

Notable investors and investment history

Gylden Pharma Limited investors
InvestorRounds
DHSCGrant
Innovate UKGrant
Vickers Venture PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 195% MoM.

  • Jun 20, 2023

    Molecular Biology Institute of Paraná participated in the round.

Gylden Pharma Limited Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gylden Pharma Limited Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gylden Pharma Limited's valuation, stock price, and market status.

Firmographic Details

HeadquartersAbingdon
Employee Range32
Year Founded2016
Last FundingNov 17, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?